Pharma Focus Europe
ThermoFisher Scientific - Go beyond the catalog

Boehringer Ingelheim Invests US$794 million (€700 million) in Austria

Introduction:

Boehringer Ingelheim palns for the construction of new biopharmaceutical production capacity. The new facility will be located in Austria.

Features:

The state-of-the-art facility will add a total of 185,000litres of biopharmaceutical production capacity with an additional 30 per cent in mammalian large scale capacity.

The new facility will be the most advanced one designed with high degree of digitalization and automation through smart technologies and artificial intelligence applications. In addition, multi-product plants and flexible line structures a wide variety of molecule formats, such as monoclonal antibodies, enzymes, cytokines and other recombinant proteins for patients with unmet medical needs are supplied.

The capacity is designed in a way that changes from one product to another can be done very easily in a short time or simultaneous production of different products.

After the completion of the new facility it is expected to create add 500 new jobs.

Specifications:

NameBoehringer Ingelheim
TypeNew Construction
BudgetUS$794 million (€700 million)
Latest Issue
Get instant
access to our latest e-book
Pall+CytivaAdvertisement
Lab Indonesia 2024Sartorius Lab Balance CleaningWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies 2024Equinix accelerated medical research...World Vaccine Congress Washington 2024EUROPEAN PHARMA OUTSOURCING SUMMIT 2024Pharma 2024